Example: Heart Attack

Search clinical trials for: Glimepiride

Total 251 results

NCT04470310

Active, not recruiting

Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination

Conditions: Type 2 Diabetes Mellitus
NCT04287387

Not yet recruiting

Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents

Conditions: Type2 Diabetes Mellitus
NCT04240171

Not yet recruiting

Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus

Conditions: Diabetes Mellitus, Type 2
NCT04237493

Completed

Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan

Conditions: Diabetes Mellitus, Type 2
NCT04183868

Recruiting

Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)

Conditions: Type 2 Diabetes; Cardiovascular Risk Factor
NCT03983551

Completed

Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas

Conditions: Type 2 Diabetes Mellitus; Proteinuria
NCT03917940

Completed

Omega 3 Fatty Acids on Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride

Conditions: Diabetic Patients
NCT03907423

Recruiting

Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin

Conditions: Diabetes Mellitus, Type 2
NCT03804411

Recruiting

Prognostic Predictors of Response to Hypoglycemic Therapy

Conditions: Diabetes Mellitus, Type 2
NCT03775902

Completed

Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development

Conditions: Type 2 Diabetes Mellitus
NCT03748810

Active, not recruiting

Head-to-head Comparison of Empagliflozin and Dapagliflozin

Conditions: Type2 Diabetes
NCT03693560

Completed

Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD

Conditions: Coronary Artery Disease; Diabetes Mellitus, Type 2
NCT03648424

Unknown status

Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses

Conditions: Type 2 Diabetes Mellitus
NCT03585777

Unknown status

Compare Serum Klotho Levels in Patients on Oral Antidiabetic Treatment

Conditions: Compare Serum Level of Klotho in Patients on Oral Antidiabetic Treatment
NCT03492580

Completed

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases
NCT03332771

Completed

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Subjects With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

Conditions: Type 2 Diabetes Mellitus
NCT03180281

Unknown status

Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell

Conditions: Type 2 Diabetes Mellitus
NCT03118713

Terminated

A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria

Conditions: Type 2 Diabetes Mellitus
NCT03081676

Completed

The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea

Conditions: Maturity-Onset Diabetes of the Young, Type 3
NCT03076112

Recruiting

Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin

Conditions: Type 2 Diabetes Mellitus
NCT03060980

Terminated

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

Conditions: Diabetes Mellitus, Type 2
NCT03009513

Completed

Teneligliptin-Glimepiride DDI Study

Conditions: Diabetes Mellitus
NCT02985242

Terminated

Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

Conditions: Diabetes Mellitus, Type II
NCT02973477

Completed

Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)

Conditions: Type2 Diabetes; Cardiovascular Diseases
NCT02964572

Completed

Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes

Conditions: Type2 Diabetes Mellitus
NCT02956044

Completed

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

Conditions: Type2 Diabetes Mellitus
NCT02954822

Completed

Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg

Conditions: Type2 Diabetes
NCT02946632

Unknown status

Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes

Conditions: Diabetes Mellitus, Type II
NCT02919059

Unknown status

Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.

Conditions: Diabetes Mellitus, Type 2
NCT02823808

Recruiting

Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function

Conditions: Diabetes
NCT02769481

Completed

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Conditions: Type 2 Diabetes Mellitus
NCT02728453

Terminated

SGLT2 Inhibition and Left Ventricular Mass

Conditions: Diabetes Mellitus Type 2
NCT02694263

Completed

Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan

Conditions: Diabetes Mellitus, Type 2
NCT02649465

Recruiting

SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD

Conditions: Non-alcoholic Fatty Liver Disease
NCT02630706

Completed

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)

Conditions: Type 2 Diabetes Mellitus
NCT02609815

Active, not recruiting

Initial Combination of Gemigliptin and Metformin on Microbiota Change

Conditions: Diabetes
NCT02567994

Completed

Tenelia Triple Combination Study

Conditions: Type 2 Diabetes Mellitus
NCT02564926

Completed

Foxiga Korea Local Phase 4 Study

Conditions: Diabetes Mellitus, Type 2
NCT02528019

Unknown status

Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors

Conditions: Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
NCT02484209

Withdrawn

DiaFrail: A Short Duration Study in Older People ( DIAFRAIL Study)

Conditions: Diabetes Mellitus
NCT02476760

Completed

Incretin-based Drugs and Acute Pancreatitis

Conditions: Diabetes Mellitus, Type 2
NCT02475499

Completed

Incretin-based Drugs and Pancreatic Cancer

Conditions: Diabetes Mellitus, Type 2
NCT02471404

Completed

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Conditions: Type 2 Diabetes Mellitus; Inadequate Glycaemic Control
NCT02462369

Unknown status

Saxagliptin's Effects on Microalbuminuria Improvement in Type 2 Diabetic Patients

Conditions: Microalbuminuria; Microalbuminuria /Creatinine Ratios ACR
NCT02456428

Completed

Incretin-based Drugs and the Risk of Heart Failure

Conditions: Type 2 Diabetes Mellitus
NCT02443922

Unknown status

Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DM

Conditions: Type 2 Diabetes
NCT02426294

Unknown status

Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin

Conditions: Type 2 Diabetes Mellitus
NCT02419612

Completed

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Conditions: Diabetes
NCT02395237

Unknown status

COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.

Conditions: Healthy
NCT02373865

Terminated

Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Conditions: Diabetes Mellitus Type 2

Search clinical trials for: Glimepiride

Recent CRA jobs

Safety Admin

Research Scientist - LCMS - Method Development

Data Analyst II – Real World Evidence

Clinical Team Manager (Local Study Manager) FSP

Senior Logistics Coordinator / Senior Sample Coordinator - Sample Management , LIMS , GMP

Associate HR Director - Business Partner

Associate Scientist - Part-time Weekends

QC Reviewer / Senior QC Reviewer - LIMS , GMP

Site Alliance Manager

Principal Clinical Database Programmer